Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL5383247 | 0.95 | LMNA (0.33) | LMNAGAACHRM2CHRM1 | |
| SCHEMBL6873304 | 0.89 | MEN1 (0.32) | — | |
| SCHEMBL30869985 | 0.84 | L3MBTL1 (0.38) | LMNAGAA | |
| SCHEMBL28353920 | 0.84 | CHRM2 (0.41) | LMNACHRM2CHRM1 | |
| SCHEMBL5497675 | 0.84 | L3MBTL1 (0.38) | LMNAGAA | |
| Water SCHEMBL28916298 | 0.83 | L3MBTL1 (0.37) | LMNAGAA | |
| SCHEMBL10781958 | 0.81 | CHRM2 (0.48) | LMNAGAACHRM2CHRM1 | |
| SCHEMBL5492629 | 0.80 | CA12 (0.38) | LMNAGAA | |
| Potassium Ion SCHEMBL8985015 | 0.80 | CA12 (0.38) | LMNAGAA | |
| Water SCHEMBL28800260 | 0.72 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858883-B2 | Method for recycling taurine mother liquor | QIANJIANG Yongan Phamaceutical CO., LTD. (CN) | 2024-01-02 | — | — | US | claimed |
| US-20230212111-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | claimed |
| EP-4201921-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | Qiangjiang Yongan Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | claimed |
| US-10107736-B2 | Hydrogel compositions and methods for electrochemical sensing | PORTLAND STATE UNIVERSITY (US) | 2018-10-23 | — | — | US | claimed |
| US-20160123865-A1 | HYDROGEL COMPOSITIONS AND METHODS FOR ELECTROCHEMICAL SENSING | PORTLAND STATE UNIVERSITY (US) | 2016-05-05 | — | — | US | claimed |
| US-11858883-B2 | Method for recycling taurine mother liquor | QIANJIANG Yongan Phamaceutical CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230212111-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4201921-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | Qiangjiang Yongan Pharmaceutical Co., Ltd. (CN) | 2023-06-28 | — | — | EP | disclosed |
| US-10107736-B2 | Hydrogel compositions and methods for electrochemical sensing | PORTLAND STATE UNIVERSITY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20160123865-A1 | HYDROGEL COMPOSITIONS AND METHODS FOR ELECTROCHEMICAL SENSING | PORTLAND STATE UNIVERSITY (US) | 2016-05-05 | — | — | US | disclosed |
| EP-1828106-B1 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | ROCHE DIAGNOSTICS GMBH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-7732160-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7294649-B2 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATINS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1828106-A2 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | Roche Diagnostics GmbH (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-20070099234-A1 | Specific detection of chitin using chitin-binding domain | NEW ENGLAND BIOLABS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7101980-B2 | Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060134711-A1 | Methamphetamine derivatives and conjugates for immunoassay | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063829-A2 | METHAMPHETAMINE DERIVATIVES AND CONJUGATES FOR IMMUNOASSAY | ROCHE DIAGNOSTICS GMBH (DE) | 2006-06-22 | — | — | WO | disclosed |
| EP-1498428-A1 | Antibodies for detecting ecstasy-class analytes | Roche Diagnostics GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| US-4247633-A | Reagent for colorimetric determination of creative phosphokinase | PABST BREWING COMPANY (US) | 1981-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060134711-A1 | Methamphetamine derivatives and conjugates for immunoassay | PNMT, COMT, MCHR1 | LMNA 3446/4885GAA 4532/4885CHRM2 13/4885 |
| US-20230212111-A1 | METHOD FOR RECYCLING TAURINE MOTHER LIQUOR | SLC6A6, SLC6A12, UGT8 | LMNA 2929/4885GAA 215/4885CHRM2 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.